Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Drug combo may better tame high blood Pressure's heart damage

NCT ID NCT07544888

Disease control Sponsor: Shaikh Zayed Hospital, Lahore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested whether combining valsartan and hydrochlorothiazide works better than valsartan alone for people with hypertensive heart disease. 118 adults aged 18-70 took part over 8 weeks. Researchers measured blood pressure, heart changes on ECG, and symptoms to see which approach is more effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Valsartan and hydrochlorothiazide
What this could lead to
If the combination works better, it could offer a more effective way to control blood pressure and reduce heart damage in people with hypertensive heart disease.
What could go wrong
This is a small, early-phase trial with only 118 participants over 8 weeks. Results may not apply to everyone, and side effects like headache, dizziness, or cough are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

118 people

The number who actually took part.

Started

Nov 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients of both the genders diagnosed with hypertensive heart disease as per operational definition. * Age18-70 years Exclusion Criteria: * Patients with drug allergies or contraindications to the medications used in this study. * Patients attending emergency unit with hypertension, those with poor compatibility and compliance. * Patients with other endocrine diseases, those with coagulation dysfunction. * Patients with mental disorders, and patients whose health conditions will be complicated by infectious or immune diseases.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart disorder hypertensive disorder hypertensive heart disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart diseases Hypertension

Contacts and locations

Locations

  • Department of Cardiology

    Lahore, Punjab Province, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.